FLEXBUMIN

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, Hong Kong SAR China, Ireland, Lithuania, Malta, Netherlands, Poland, Singapore, Spain.

Active ingredients

The drug FLEXBUMIN contains one active pharmaceutical ingredient (API):

1	Albumin UNII ZIF514RVZR - ALBUMIN HUMAN
	Human albumin accounts quantitatively for more than half of the total protein in the plasma and represents about 10% of the protein synthesis activity of the liver. The most important physiological functions of albumin results from its contribution to oncotic pressure of the blood and transport function. Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins.
	Read more about Albumin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B05AA01	Albumin	B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05A Blood and related products → B05AA Blood substitutes and plasma protein fractions
Discover more medicines within B05AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1277153, 1277164, 1566840, 1566851
ES	Centro de información online de medicamentos de la AEMPS	69708
HK	Department of Health Drug Office	57632
HR	Agencija za lijekove i medicinske proizvode	HR-H-166205993
LT	Valstybinė vaistų kontrolės tarnyba	1024365, 1032667, 1068137, 1068138
MT	Medicines Authority	MA1047/00301, MA1047/00302
NL	Z-Index G-Standaard, PRK	91669
PL	Rejestru Produktów Leczniczych	100181470
SG	Health Sciences Authority	13582P, 13583P
US	FDA, National Drug Code	0944-0493, 0944-0495